Literature DB >> 22095001

Prediction of late (24-hour) radioactive iodine uptake using early (3-hour) uptake values in Japanese patients with Graves' disease.

Yoshinori Osaki1, Kanako Sakurai, Zenei Arihara, Masahiro Hata, Hiroshi Fukazawa.   

Abstract

Measurement of 24-hour radioactive iodine uptake (RAIU), which is commonly used to calculate the dose of radioiodine (RI) therapy, cannot be accomplished in a single day. The purpose of this study was to predict 24-hour RAIU from 3-hour RAIU in Japanese patients with Graves' disease, and to investigate other factors that could be used to predict 24-hour RAIU. A total of 66 Japanese patients (14 men and 52 women; age, 17-83 years) with Graves' disease who had undergone both 3-hour and 24-hour ¹²³I RAIU measurements between January 2006 and September 2011 were included in this study. Stepwise multiple regression analyses were performed in order to identify factors that could be used to predict 24-hour RAIU. The investigated factors were gender, age, thyroid volume, TSH, free thyroxine (FT4), free triiodothyronine (FT3), serum creatinine, second generation assay TSH receptor antibody (TRAb2), antithyroid drugs discontinuation period (ADP), iodine restriction period and 3-hour RAIU. The ADP was converted to an ordinal scale ADP score (ADPS) for multiple regression analyses. Multiple regression analyses showed that 3-hour RAIU (P < 0.001), FT3 (P < 0.001) and ADPS (P < 0.001) were statistically significant predictive factors of 24-hour RAIU. The relationship between 24-hour RAIU (LU) and 3-hour RAIU (EU), FT3 and ADPS was: LU = 11.5 + 29.1 × log₁₀ EU + 23.0 × log₁₀ FT3 - 2.7 × ADPS (r = 0.82, P < 0.001). The present results indicate that prediction of LU from EU, FT3 and ADPS is feasible in Japanese patients with Graves' disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22095001     DOI: 10.1507/endocrj.ej11-0279

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  4 in total

1.  Differentiation between Graves' disease and painless thyroiditis by diffusion-weighted imaging, thyroid iodine uptake, thyroid scintigraphy and serum parameters.

Authors:  Zhaowei Meng; Guizhi Zhang; Haoran Sun; Jian Tan; Chunshun Yu; Weijun Tian; Weidong Li; Zhiqiang Yang; Mei Zhu; Qing He; Yujie Zhang; Shugao Han
Journal:  Exp Ther Med       Date:  2015-04-17       Impact factor: 2.447

2.  Real-time quantitation of thyroidal radioiodine uptake in thyroid disease with monitoring by a collar detection device.

Authors:  Prasanna Santhanam; Lilja Solnes; Tanmay Nath; Jean-Paul Roussin; David Gray; Eric Frey; George Sgouros; Paul W Ladenson
Journal:  Sci Rep       Date:  2021-09-16       Impact factor: 4.379

3.  Analysis of risk factors of rapid thyroidal radioiodine-131 turnover in Graves' disease patients.

Authors:  Ruiguo Zhang; Jian Tan; Renfei Wang; Guizhi Zhang; Qiang Jia; Zhaowei Meng; Yueqian Zhang
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

4.  Calculation of therapeutic activity of radioiodine in Graves' disease by means of Marinelli's formula, using technetium (99mTc) scintigraphy.

Authors:  Piotr Szumowski; Małgorzata Mojsak; Saeid Abdelrazek; Monika Sykała; Anna Amelian-Fiłonowicz; Dorota Jurgilewicz; Janusz Myśliwiec
Journal:  Endocrine       Date:  2016-08-24       Impact factor: 3.633

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.